Literature DB >> 23442048

Catalytic Ugi-type condensation of α-isocyanoacetamide and chiral cyclic imine: access to asymmetric construction of several heterocycles.

Liang Xia1, Sheng Li, Ruijiao Chen, Kai Liu, Xiaochuan Chen.   

Abstract

Several novel heterocycles have been constructed asymmetrically on the basis of a catalytic Ugi-type condensation of α-isocyanoacetamide and chiral cyclic imine. The combination of phenylphosphilic acid and trifluoroethanol is exploited to promote an Ugi-type reaction with α-isocyanoacetamide for the first time. By means of this reaction, chiral 3-oxazolyl morpholin-2-one/piperazin-2-one derivatives are synthesized with high yields and excellent stereoselectivities. As electron-rich azadienes, these condensation products are further transformed to fused tricyclic frameworks by treatment with appropriate dienophiles such as maleic anhydride and unsaturated acyl chlorides via domino processes. Moreover, a one-pot, three-component synthesis of the chiral tricyclic frameworks from isocyanoacetamide, imine, and maleic anhydride is also feasible.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23442048     DOI: 10.1021/jo4000702

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  3 in total

1.  New Three-Component Bicyclization Leading to Densely Functionalized Pyrazolo[3,4-d]thiazolo[3,2-a]pyrimidines.

Authors:  Wen-Juan Hao; Peng Zhou; Fei-Yue Wu; Bo Jiang; Shu-Jiang Tu; Guigen Li
Journal:  European J Org Chem       Date:  2016-03-29

2.  Four-component bicyclization approaches to skeletally diverse pyrazolo[3,4-b]pyridine derivatives.

Authors:  Xing-Jun Tu; Wen-Juan Hao; Qin Ye; Shuang-Shuang Wang; Bo Jiang; Guigen Li; Shu-Jiang Tu
Journal:  J Org Chem       Date:  2014-11-04       Impact factor: 4.354

Review 3.  Isocyanide-Based Multicomponent Reactions for the Synthesis of Heterocycles.

Authors:  András Váradi; Travis C Palmer; Rebecca Notis Dardashti; Susruta Majumdar
Journal:  Molecules       Date:  2015-12-23       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.